1. Home
  2. KALV vs BWMN Comparison

KALV vs BWMN Comparison

Compare KALV & BWMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$16.12

Market Cap

551.2M

Sector

Health Care

ML Signal

HOLD

BWMN

Bowman Consulting Group Ltd.

HOLD

Current Price

$34.53

Market Cap

620.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
BWMN
Founded
N/A
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
551.2M
620.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
KALV
BWMN
Price
$16.12
$34.53
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$30.00
$40.90
AVG Volume (30 Days)
1.3M
124.9K
Earning Date
03-11-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.94
Revenue
$1,426,000.00
$474,277,000.00
Revenue This Year
N/A
$17.21
Revenue Next Year
$204.16
$9.75
P/E Ratio
N/A
$36.96
Revenue Growth
N/A
16.73
52 Week Low
$8.74
$17.90
52 Week High
$19.00
$45.83

Technical Indicators

Market Signals
Indicator
KALV
BWMN
Relative Strength Index (RSI) 54.89 46.05
Support Level $15.22 $33.13
Resistance Level $16.16 $37.50
Average True Range (ATR) 0.88 1.49
MACD -0.01 -0.14
Stochastic Oscillator 76.95 30.89

Price Performance

Historical Comparison
KALV
BWMN

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About BWMN Bowman Consulting Group Ltd.

Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape and Architecture/Planning.

Share on Social Networks: